[
  {
    "ts": null,
    "headline": "Precipio: Cash Flow Positivity May Remove Going Concern Language",
    "summary": "Deep Sail Capital highlights Precipioâs path to cash flow positivity and niche growth in cancer diagnostics. See why its turnaround story deserves a closer look.",
    "url": "https://finnhub.io/api/news?id=c384ce4b6028ab55765fe4386e474bfc60535242c93ca10f772e172fe22d64de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754595900,
      "headline": "Precipio: Cash Flow Positivity May Remove Going Concern Language",
      "id": 136263091,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295493003/image_1295493003.jpg?io=getty-c-w1536",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "Deep Sail Capital highlights Precipioâs path to cash flow positivity and niche growth in cancer diagnostics. See why its turnaround story deserves a closer look.",
      "url": "https://finnhub.io/api/news?id=c384ce4b6028ab55765fe4386e474bfc60535242c93ca10f772e172fe22d64de"
    }
  },
  {
    "ts": null,
    "headline": "Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types",
    "summary": "Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research collaboration will investigate the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test, as an aid in postoperative therapy decisions for two cancer types: cut",
    "url": "https://finnhub.io/api/news?id=452ba7453732b29570499dce637f697abd2b96ef1c693d726a4e3d814613743d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754572080,
      "headline": "Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types",
      "id": 136246891,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research collaboration will investigate the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test, as an aid in postoperative therapy decisions for two cancer types: cut",
      "url": "https://finnhub.io/api/news?id=452ba7453732b29570499dce637f697abd2b96ef1c693d726a4e3d814613743d"
    }
  }
]